IGI Logo

Weak print; quarterly volatility continues

* P&G Hygiene & Healthcare’s (PGHH) 1QFY27 revenue declined 5% YoY (miss) to INR8.9b on a flat base. Revenue growth was weak, with the business continuing to exhibit high quarterly performance volatility.

* Gross margin contracted 630bp YoY (470bp QoQ) to 57.3%, impacted by commodity cost inflation due to geopolitical uncertainties. Employee costs increased 12% YoY, A&P spending jumped 21% YoY, and other expenses declined 4% YoY. Despite raw material cost pressure, PGHH continued to invest in innovation and brand building. Consequently, EBITDA margin contracted 930bp YoY (410bp QoQ) to 19.1%, while EBITDA declined 36% YoY to INR1.7b (est. INR2.7b).

* PGHH exhibits significant volatility on a quarterly basis, with profitability impacted by high input costs and continued investment in brands. We model EBITDA margin of 26.0-26.5% during FY27 and FY28.

* Management at PGHH’s analyst meet stated that they expect the operating environment to remain challenging as macro inflation is expected to keep consumers value-conscious. PGHH noted soft demand trends across both rural and urban markets. We model a CAGR of 6%/5%/5% in revenue/EBITDA/PAT over FY26-28E. The stock has corrected ~35% in last one year. Given the volatility in margins, we find other consumer names relatively better than PGHH for the growth outlook it offers. We maintain Neutral with a revised TP of INR9,500 (based on 35x Mar’28E EPS).

Miss on all fronts; margin pressure weighs on earnings

* Revenue down 5%: PGHH reported a 5% YoY decline in revenue to INR8.9b (est. INR10b) on a base of 0.6% growth. Revenue growth remains subdued, with quarterly performance remaining highly volatile.

* Sharp margin contraction: Gross margin declined 630bp YoY to 57.3% (est. 63.5%), impacted by commodity cost fluctuations amid geopolitical uncertainties. Employee costs increased 12% YoY, A&P spending rose 21% YoY, and other expenses declined 4% YoY. Despite raw material inflation, the company continued to invest in innovation and advertising. As a result, EBITDA margin contracted 930bp YoY to 19.1% (est. 26.5%).

* Weak profitability: EBITDA declined 36% YoY to INR1.7b (est. INR2.7b). PBT declined 36% YoY, while adj. PAT fell 34% YoY to INR1.3b (est. INR2.0b).

Valuation and view

* We cut our EPS estimates by 5-6% for FY27 and FY28.

* Two factors make PGHH an attractive long-term core holding:

1) robust growth potential in the feminine hygiene segment (65-68% of sales mix) and the potential for market share gains, aided by strategic initiatives, including the fortification of significant market advantages

2) potential for higher margin gains from the long-term trend of premiumization in the feminine hygiene segment.

* With a portfolio of essentials and healthcare, PGHH remains focused on product innovation-led customer acquisition. While penetration play will continue, it is expected to proceed at a stable pace despite the high scope of user additions. Further, we do not see any medium-term upside trigger.

* We maintain Neutral with a revised TP of INR9,500 (based on 35x Mar’28E EPS).

For More Research Reports : Click Here 

For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412